Retatrutide Prescribed Online to Texas Residents
Medical Weight Loss Treatment in Texas
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Texas
Everything's bigger in Texas—including the challenges of accessing healthcare across 268,000 square miles. OmniRx Health serves the entire Lone Star State, from the Houston energy corridor to the Dallas-Fort Worth metroplex, the tech hub of Austin to the border communities of the Rio Grande Valley. Whether you're a rancher in the Panhandle, a worker in the Permian Basin, or a professional in San Antonio, our telehealth platform brings expert care to your corner of Texas.
Our providers are licensed by the Texas Medical Board to deliver comprehensive telehealth services across the Lone Star State.
Texas's vast pharmacy network from Houston to Dallas to El Paso ensures prescription access, with specialized compounding pharmacies available.
Texas has modernized its telehealth laws to support comprehensive virtual care delivery across the state's 254 counties.
Texas requires telehealth coverage parity for many insurance plans, and Medicaid has expanded virtual care benefits.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Texas?
- Yes, telehealth is fully legal in Texas. The state has modernized its laws to support virtual healthcare delivery, allowing licensed providers to offer comprehensive services.
- Can rural Texas residents use telehealth?
- Telehealth is transforming rural Texas healthcare. Residents in West Texas, the Hill Country, and other remote areas can access specialists without driving hours to urban centers.
- Does Texas Medicaid cover telehealth?
- Yes, Texas Medicaid covers telehealth services for eligible members. The state has expanded virtual care coverage to improve access across all 254 counties.